Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0PR2Q
|
|||
| Former ID |
DNC008230
|
|||
| Drug Name |
Pr-RYYRIK-NH2
|
|||
| Synonyms |
CHEMBL403807
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C45H72N14O8
|
|||
| Canonical SMILES |
CCC(C)C(C(=O)NC(CCCCN)C(=O)N)NC(=O)C(CCCN=C(N)N)NC(=O)C(CC1=CC=C(C=C1)O)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CCCN=C(N)N)NC(=O)CC
|
|||
| InChI |
1S/C45H72N14O8/c1-4-27(3)37(43(67)55-31(38(47)62)15-9-10-22-46)59-40(64)33(17-12-24-53-45(50)51)56-41(65)35(26-29-18-20-30(60)21-19-29)58-42(66)34(25-28-13-7-6-8-14-28)57-39(63)32(54-36(61)5-2)16-11-23-52-44(48)49/h6-8,13-14,18-21,27,31-35,37,60H,4-5,9-12,15-17,22-26,46H2,1-3H3,(H2,47,62)(H,54,61)(H,55,67)(H,56,65)(H,57,63)(H,58,66)(H,59,64)(H4,48,49,52)(H4,50,51,53)/t27-,31-,32-,33-,34-,35-,37-/m0/s1
|
|||
| InChIKey |
DWZCXYUZSXSRCU-OQYWAUBWSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Nociceptin receptor (OPRL1) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist. Bioorg Med Chem. 2008 Mar 1;16(5):2635-44. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.